Nicox Announces Senior Management Change
September 18, 2020
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced a change in Nicox management. Dr. Tomas Navratil, PhD, Executive Vice President & Head of Research & Development of the Nicox Group and General Manager of Nicox Ophthalmics, Inc. will be leaving Nicox on October 16, 2020 to pursue other opportunities. The Company has initiated a search for a successor. In the interim, Dr. José Boyer, the current Vice President and Head, Clinical Development, will be appointed as Interim Head of R&D, effective October 16, 2020.
Michele Garufi, Chairman and Chief Executive Officer of Nicox, said: “We are very appreciative of Dr. Navratil’s contributions to Nicox and the excellent R&D progress achieved across all programs in Nicox’s pipeline during his tenure and we wish him great success in his future endeavours. I am confident that under Dr. Boyer’s leadership the R&D team will continue to successfully deliver on key milestones in the NCX 470 trials and the forthcoming NCX 4251 trial.”